" class="no-js "lang="en-US"> Plume, the Leading Gender-Affirming Virtual Care Provider Announces $24M in Series B Funding to Expand Coverage Nationwide - Medtech Alert
Wednesday, May 22, 2024

Plume, the Leading Gender-Affirming Virtual Care Provider Announces $24M in Series B Funding to Expand Coverage Nationwide

Plume, the market-leading provider of virtual care services purposefully designed for the health care needs of the transgender community, today announced their Series B funding round of $24 million, led by Transformation Capital with participation from General Catalyst and Townhall Ventures. The growth investment in Plume will support the company in fulfilling its mission to transform health care for every trans life by creating access to high quality, safe gender-affirming care. As the world’s leading virtual care provider for gender-affirming care, Plume will use these resources to expand coverage nationwide and into virtual primary care, ensure Plume is covered by insurance, and provide support that trans and gender diverse people and their families deserve.

“As a trans woman and physician, I started Plume to offer a supportive space for trans Americans as they navigate our nation’s broken health care system,” said Dr. Jerrica Kirkley, Plume’s Co-Founder and Chief Medical Officer. “With today’s announcement, we are on track to reach our goal of increasing access to high-quality, gender-affirming care to patients across the U.S. in both urban areas and coverage deserts. Knowing the hurdles trans Americans face when accessing care, I’m encouraged to reach this benchmark and I look forward to Plume’s growth in the future. I want to thank Transformation Capital, General Catalyst, and Townhall Ventures for their partnership in transforming health care for every trans life.”

The visibility of the trans community is growing at an exponential rate as younger generations more readily openly identify as trans and gender diverse. Gen Z  identifies as trans at nearly four times the rate of baby boomers and is statistically the queerest generation in history. Trans individuals have unique medical, legal, and socio-emotional needs distinct from those of the broader cisgender LGBQ+ population that are commonly unmet by the status quo. Plume is the only digital-health company entirely dedicated to services for trans and gender diverse individuals and their families and is uncompromisingly focused on providing the best care experience available.

“Since launching in 2019, Plume has strived to bring the trans community the deeply personalized health care they deserve,” said Dr. Matthew Wetschler, Plume’s Co-Founder and Chief Executive Officer. “Amidst growing anti-trans rhetoric nationwide, Plume’s model offers unmatched access to health care for trans Americans. Today’s announcement only reinforces our goal of expanding that coverage and eliminating barriers to quality care.”

Access to safe health care is woefully inadequate across the ~2 million Americans that constitute the trans community. More than 30% of trans people avoid health care for fear of discrimination and more than 60% of trans people in urban areas have had to access medications outside of the clinical system. Plume has a clinical care model purposefully designed by a trans-led clinical team to ensure a positive, high-quality health care experience.

We are thrilled to partner with Plume’s Co-Founders, Dr. Matthew Wetschler & Dr. Jerrica Kirkley, and their incredible team. Our firm has deep empathy and compassion for underserved communities – we believe the trans community deserves a better, more accessible care experience that is unfortunately not available to many in our health care system today. Plume is positioned to be a medical home for this important and growing community,” said Jenna Ciotti, Vice President at Transformation Capital.

While Plume continues to work towards gender-affirming care being covered by insurance, no insurance is necessary to become a member and receive care. Members pay $99 a month and receive 24/7 access to gender-affirming care, personal consultations, lab testing, facilitated support groups, medical letters of support for surgery and name and gender marker changes, and home delivery of prescriptions and gender-affirming medication as medically appropriate. Plume eliminates these barriers by making gender-affirming care accessible for anyone who needs it without ever having to step into a doctor’s office.

The research shows that gender-affirming care is life-saving and a clinical imperative. As anti-trans rhetoric and sentiment continues, guaranteeing access to trans-specific care is more important now than ever. This funding will support Plume’s expansion that is critically important to addressing the unique needs of the trans community.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more